InsiderSignalSign in

← Insider buys

FMR LLC has bought stock on 2 days since Apr 2018

See Remark 1 at Beam Therapeutics Inc., and 9 other companies

SEC CIK 0000315066 · Filings on SEC.gov ↗

$1.9MBought

$101.8MSold

Apr 3Last buy

FMR LLC's record

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Companies

Every filing

55 filings since Apr 2016, newest first

Beam Therapeutics Inc.

See Remark 1

$10.0M−25.0%Jun 29

Beam Therapeutics Inc.

See Remark 1

$27.5M−18.0%Feb 15

Beam Therapeutics Inc.

See Remark 1, 10%

Beam Therapeutics Inc.

See Remark 1, 10%

Verve Therapeutics, Inc.

See Remark 1, 10%

$3.4M−22.0%Jul 14

Verve Therapeutics, Inc.

See Remark 1, 10%

$607K−5.0%Jul 6

Verve Therapeutics, Inc.

See Remark 1, 10%

$822K−6.0%Jul 1

Beam Therapeutics Inc.

See Remark 1, 10%

Verve Therapeutics, Inc.

See Remark 1, 10%

Verve Therapeutics, Inc.

See Remark 1, 10%

$389K−2.0%Feb 11

Verve Therapeutics, Inc.

See Remark 1, 10%

$1.0M−4.0%Feb 3

Verve Therapeutics, Inc.

See Remark 1, 10%

$4.9M−15.0%Jan 28

Orchard Therapeutics Plc

See Remark 1, 10%

$14.3M−17.0%Feb 10

Orchard Therapeutics Plc

See Remark 1, 10%

Precision Biosciences Inc

See Remark 1

$800K+1.0%Apr 3

Viewray, Inc.

See Remark 1

$2.0M−25.0%Aug 10

Viewray, Inc.

See Remark 1, 10%

$1.8M−18.0%Aug 8

Viewray, Inc.

See Remark 1, 10%

$3.8M−25.0%Aug 6

Viewray, Inc.

See Remark 1, 10%

$1.5M−9.0%Aug 2

Viewray, Inc.

See Remark 1, 10%

$3.0M−15.0%Jul 31

Viewray, Inc.

See Remark 1, 10%

$3.6M−15.0%Jul 27

Unum Therapeutics Inc.

See Remark 1

$1.1M+4.0%Apr 5

Viewray, Inc.

See Remark 1

$722K−2.0%Apr 27

Viewray, Inc.

See Remark 1, 10%

$678K−2.0%Apr 25

Viewray, Inc.

See Remark 1, 10%

$698K−2.0%Apr 21

Viewray, Inc.

See Remark 1, 10%

$776K−2.0%Apr 19

Viewray, Inc.

See Remark 1, 10%

$862K−2.0%Apr 17

Viewray, Inc.

See Remark 1, 10%

$1.3M−3.0%Apr 13

Viewray, Inc.

See Remark 1, 10%

$1.4M−3.0%Apr 11

Viewray, Inc.

See Remark 1, 10%

$411K−1.0%Apr 10

Viewray, Inc.

See Remark 1, 10%

$1.6M−3.0%Apr 6

Viewray, Inc.

See Remark 1, 10%

$1.8M−3.0%Apr 4

Viewray, Inc.

See Remark 1, 10%

Proteostasis Therapeutics, Inc.

See Remark 1

$324K−9.0%Mar 15

Proteostasis Therapeutics, Inc.

See Remark 1, 10%

$301K−9.0%Mar 13

Proteostasis Therapeutics, Inc.

See Remark 1, 10%

$354K−9.0%Mar 10

Proteostasis Therapeutics, Inc.

See Remark 1, 10%

$781K−16.0%Mar 8

Proteostasis Therapeutics, Inc.

See Remark 1, 10%

$626K−11.0%Mar 6

Proteostasis Therapeutics, Inc.

See Remark 1, 10%

$658K−10.0%Mar 2

Aclaris Therapeutics, Inc.

See Remark 1, 10%

Coherus Biosciences, Inc.

See Remark 1

$3.0M−22.0%Aug 10

Coherus Biosciences, Inc.

See Remark 1, 10%

$1.4M−10.0%Aug 8

Regenxbio Inc.

See Remark 1

$227K−4.0%May 18

Regenxbio Inc.

See Remark 1, 10%

$187K−2.0%May 17

Regenxbio Inc.

See Remark 1, 10%

$73K−1.0%May 13

Regenxbio Inc.

See Remark 1, 10%

$260K−4.0%May 12

Regenxbio Inc.

See Remark 1, 10%

$105K−2.0%May 10

Regenxbio Inc.

See Remark 1, 10%

$65K−1.0%May 4

Regenxbio Inc.

See Remark 1, 10%

$51K−1.0%May 2

Regenxbio Inc.

See Remark 1, 10%

$373K−4.0%Apr 29

About FMR LLC

FMR LLC is a U.S.-based investment management firm and the corporate parent associated with Fidelity Investments, one of the world’s largest asset managers. It is best known for providing investment management, brokerage, retirement, and financial services across mutual funds, workplace savings, and institutional accounts. In Beam Therapeutics’ recent insider-trading filings, FMR LLC was reported as a 10% owner of the company and disclosed indirect open-market sales of Beam shares through affiliated investment vehicles.(

The firm is led by Abigail P. Johnson, who is identified in the filing as FMR LLC’s Chairman and Chief Executive Officer; the filing also notes that members of the Johnson family are the predominant owners of the firm’s Series B voting shares through direct ownership and trusts.( In Beam Therapeutics ownership data, FMR LLC appears as a significant institutional shareholder, reflecting its broader role as a large investment manager with substantial holdings across public markets.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.